Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era
Marco Galluzzo, Lorenzo Tofani, Luca Bianchi, Marina Talamonti
Abstract
INTRODUCTION: : In our practice, there is no evidence favoring the discontinuation of secukinumab in these patients. We also present a brief commentary on the use of biological agents in patients with moderate-to-severe plaque psoriasis.
Topics & Concepts
SecukinumabMedicinePlaque psoriasisCoronavirus disease 2019 (COVID-19)PsoriasisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Cohort2019-20 coronavirus outbreakImmunologyBiological drugsIntensive care medicineDiseaseVirologyInternal medicinePsoriatic arthritisInfectious disease (medical specialty)OutbreakPsoriasis: Treatment and PathogenesisAutoimmune Bullous Skin DiseasesSarcoidosis and Beryllium Toxicity Research